Welcome to our dedicated page for Nexalin Tech SEC filings (Ticker: NXL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nexalin Technology, Inc. (Nasdaq: NXL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Nexalin’s capital markets activity, governance, and material events related to its development and commercialization of non-invasive neurostimulation medical devices.
Through this page, users can review Form 8-K current reports describing events such as amendments to equity distribution agreements, at-the-market (ATM) offering programs, and changes in executive leadership or compensation arrangements. For example, Nexalin has reported an amendment to its equity distribution agreement that governs sales of common stock under a shelf registration statement on Form S-3, as well as the expiration and delisting of certain warrants while its common stock continues to trade under the NXL symbol.
Filings also include Form 25 notifications, such as the removal of specific warrant classes from listing on the Nasdaq Stock Market, and other exhibits that document legal opinions, material contracts, and related items. Together, these records help investors understand how Nexalin finances its operations, manages its securities, and responds to exchange listing requirements.
On Stock Titan, Nexalin’s filings are updated in near real time from the SEC’s EDGAR system. AI-powered tools summarize lengthy documents, highlight key sections, and make it easier to identify information about equity offerings, listing status changes, and other material developments. Users can quickly scan for relevant items across Nexalin’s 8-Ks, registration statements, and related exhibits without reading every page of the original filings.
Nexalin Technology, Inc. reports that its publicly traded warrants issued as part of its initial public offering have expired. On September 22, 2025, at 5:00 PM Eastern time, these warrants, each exercisable for one share of common stock at an exercise price of $4.15, terminated in accordance with their original terms.
The Nasdaq Stock Market filed a Form 25 with the SEC to reflect that the warrants had expired and were delisted. The company’s common stock is unaffected by this change and will continue to trade on the Nasdaq Capital Market under the symbol NXL.
Nexalin Technology, Inc. (symbol NXLIW) is the subject of a Form 25 notification filed under the Securities Exchange Act to remove a class of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing names the issuer and provides its principal office at 1776 Yorktown, Suite 550, Houston, Texas 77056 and a contact telephone number as listed in the form.
The document duplicates the regulatory checkboxes for rule provisions governing removal and states that Nasdaq certifies it has complied with the applicable procedures to strike or withdraw the class of securities. The form includes the standard OMB approval legend and a note that the Form 25 and attached notice comply with the applicable rules.
Nexalin Technology, Inc. (NXL) filed a Form 144 notice reporting a proposed sale of 23,150 shares of an "Other" class of securities to be executed through Ladenburg Thalmann & Co. Inc. on the NASDAQ with an approximate sale date of 09/10/2025. The filing lists the number of shares outstanding as 1,718,000 and an aggregate market value of 402.81 (as reported). The shares were acquired on 09/16/2022 in an open market purchase from Maxim Group, with payment recorded as cash/check. The filer indicates no securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.